摘要
目的 比较多西他赛与伊立替康分别联合希罗达治疗晚期胃癌的近期疗效和不良反应。方法 65例患者随机分为两组，A组33例应用多西他赛联合希罗达，B组32例联合应用多西他赛、伊立替康和联合希罗达，均化疗2周期以上。结果 A组有效18例（54．54％），中位无进展生存期（PFS）为6．1个月；B组分别为17例（53．13％）和6．2个月（均P〉0．05）。A组贫血较重，B组腹泻较重。结论 两种方案对晚期胃癌患者均有较好疗效且疗效相当，不良反应可以耐受。
Objective To compare the short-term effect of Docetaxe and Irinotecan combined with Xeloda in treatment of end stage gastric cancer. Methods 65 patients with advanced gastric cancer were randomly divided into two groups. 33 patients in group A received Docetaxe plus Xeloda and 32 patients in group B received Irinotecan plus Xeloda. At least two treatment cycles were completed. Results The overall response rate is 54.54 % （ A ） and 53.13% （B） ,and the median progression-free survival was 6.1 months and 6.2 months. Patients in group A experienced more anemia, and patients in group B, diarrhoea. Conclusion The effects of Docetaxe or Irinotecan combined with Xeloda in the treatment of advanced gastric cancer are comparable and well tolerated.
出处
《中国综合临床》
北大核心
2008年第9期938-940,共3页
Clinical Medicine of China
